Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) – the current challenges for its management

Czech version

Authors: Zuzana Zafarová
Published in: AtheroRev 2025; 10(2): 127-134
Category:

Overview

The new name of the nosological entity –⁠ Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) reflects more accurately the metabolic nature of the disease and its association with other cardiometabolic disorders due to obesity, unhealthy diet and lack of exercise than the original NAFLD/NASH. This poses new challenges for general practitioners, (gastro)hepato(entero)logists, endocrinologists, lipidologists and obesitologists, but also for the entire healthcare system to improve prevention, detection and early treatment.

Keywords:

NAFLD – NASH – lifestyle modification – tirzepatide – efruxifermin – FIB4-index – lanifibranor – MASLD – MetALD – pegozafermin – resmetirom – ursodeoxycholic acid (UDCA)

Sources

Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 2013; 28(Suppl 1): 68–76. Dostupné z DOI: <https://doi: 10.1111/jgh.12212>.

Sanyal AJ, Brunt EM, Kleiner DE et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54(1): 344–353. Dostupné z DOI: <https://doi: 10.1002/hep.24376>.

Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52(5): 1836–1846. Dostupné z DOI: <https://doi: 10.1002/hep.24001>.

Abenavoli L, Scarlata GGM, Scarpellini E et al. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome. Medicina (Kaunas) 2023; 59(3): 594. Dostupné z DOI: <https://doi: 10.3390/medicina59030594>.

Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62(1 Suppl): S47–64. Dostupné z DOI: <https://doi: 10.1016/j.jhep.2014.12.012>.

Puri P, Liangpunsakul S, Christensen JE et al. [TREAT Consortium]. The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. Hepatology 2018; 67(4): 1284–1302. Dostupné z DOI: <https://doi: 10.1002/hep.29623>.

Rinella ME, Lazarus JV, Ratziu V et al. [NAFLD Nomenclature consensus group]. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78(6): 1966–1986. Dostupné z DOI: <https://doi: 10.1097/HEP.0000000000000520>.

Staufer K, Huber-Schönauer U, Strebinger G et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J Hepatol 2022; 77(4): 918–930. Dostupné z DOI: <https://doi: 10.1016/j.jhep.2022.04.040>.

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet 2017; 389(10064): 37–55. Dostupné z DOI: <https://doi: 10.1016/S0140–6736(16)31919–5>.

Riazi K, Azhari H, Charette JH et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022; 7(9): 851–861. Dostupné z DOI: <https://doi: 10.1016/S2468–1253(22)00165–0>.

Le MH, Yeo YH, Zou B et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol 2022; 28(4): 841–850. Dostupné z DOI: <https://doi: 10.3350/cmh.2022.0239>.

Estes C, Razavi H, Loomba R et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018; 67(1): 123–133. Dostupné z DOI: <https://doi: 10.1002/hep.29466>.

Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol 2015; 62(1 Suppl): S65-S75. Dostupné z DOI: <https://doi: 10.1016/j.jhep.2015.02.041>.

Rinella ME, Lominadze Z, Loomba R et al. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therap Adv Gastroenterol 2016; 9(1): 4–12. Dostupné z DOI: <https://doi: 10.1177/1756283X15611581>.

Zelber-Sagi S, Godos J, Salomone F. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therap Adv Gastroenterol 2016; 9(3): 392–407. Dostupné z DOI: <https://doi: 10.1177/1756283X16638830>.

Lazarus JV, Mark HE, Villota-Rivas M et al. [NAFLD policy review collaborators]. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? J Hepatol 2022; 76(4): 771–780. Dostupné z DOI: <https://doi: 10.1016/j.jhep.2021.10.025>.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis –⁠ 2021 update. J Hepatol 2021; 75(3): 659–689. Dostupné z DOI: <https://doi: 10.1016/j.jhep.2021.05.025>.

Česká hepatologická společnost. Doporučený postup ČHS pro diagnostiku a léčbu NAFLD 2019 & 2023. Dostupné z WWW: <https://www.ces-hep.cz/doporucene-postupy-ceske-hepatologicke-spolecnosti>.

Kjaergaard M, Lindvig KP, Thorhauge KH et al. Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 Individuals. Clin Gastroenterol Hepatol 2024; 22(5): 1037–1047.e9. Dostupné z DOI: <https://doi: 10.1016/j.cgh.2023.12.018>.

Sanyal AJ, Munoz B, Cusi K et al. [TARGET-NASH Investigators]. Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort. Clin Gastroenterol Hepatol 2023; 21(11): 2889–2900.e10. Dostupné z DOI: <https://doi: 10.1016/j.cgh.2023.02.024>.

Banach M, Lewek J, Surma S et al. The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis. Eur J Prev Cardiol 2023; 30(18): 1975–1985. Dostupné z DOI: <https://doi: 10.1093/eurjpc/zwad229>.

Jang H, Kim Y, Lee DH et al. Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease. JAMA Intern Med 2024; 184(4): 375–383. Dostupné z DOI: <https://doi: 10.1001/jamainternmed.2023.8029>.

Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‚mechanisms of action and clinical use in hepatobiliary disorders‘. J Hepatol 2001; 35(1): 134–146. Dostupné z DOI: <https://doi: 10.1016/s0168–8278(01)00092–7>.

Elhini SH, Wahsh EA, Elberry AA et al. The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals (Basel) 2022; 15(12): 1516. Dostupné z DOI: <https://doi: 10.3390/ph15121516>.

Shen H, Zhang Y, Ding H et al. Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cell Physiol Biochem 2008; 22(1–4): 1–14. Dostupné z DOI: <https://doi: 10.1159/000149779>.

Simental-Mendía M, Sánchez-García A, Simental-Mendía LE. Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials. Br J Clin Pharmacol 2020; 86(8): 1476–1488. Dostupné z DOI: <https://doi: 10.1111/bcp.14311>.